Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Figure 1
Effect of MRD pre-HCT on transplant outcome. (a) Cumulative incidence of relapse after HCT. One- and 3-year estimates of relapse for patients without MRD pre-HCT were 12% and 17%, respectively, compared to 32% and 38% for patients with MRD pre-HCT. (b) Overall survival after HCT. One- and 3-year estimates of overall survival for patients without MRD pre-HCT were 75% and 68%, respectively, compared to 44% and 40% for patients with MRD pre-HCT. (c) Relapse-free survival. One- and 3-year estimates of relapse-free survival for patients without MRD pre-HCT were 69% and 61%, respectively, compared to 41% and 34% for patients with MRD pre-HCT.